发明公开
- 专利标题： Modified CEA and uses thereof
- 专利标题（中）： 改性CEA和相应的用途
-
申请号： EP05004454.4申请日： 2001-07-27
-
公开(公告)号： EP1561817A3公开(公告)日： 2005-09-14
- 发明人: Berinstein, Neil , Tartaglia, James , Tine, John A. , Panicali, Dennis L. , Gritz, Linda , Schlom, Jeffrey
- 申请人： Aventis Pasteur Limited , Therion Biologics , National Cancer Institute
- 申请人地址： Connaught Campus, 1755 Steeles Avenue West Toronto, Ontario M2R 3T4 CA
- 专利权人： Aventis Pasteur Limited,Therion Biologics,National Cancer Institute
- 当前专利权人： Aventis Pasteur Limited,Therion Biologics,National Cancer Institute
- 当前专利权人地址： Connaught Campus, 1755 Steeles Avenue West Toronto, Ontario M2R 3T4 CA
- 代理机构： Nachshen, Neil Jacob
- 优先权： US222043P 20000731
- 主分类号： C12N15/12
- IPC分类号： C12N15/12 ; C12N15/86 ; C12N7/01 ; C12N5/10 ; C07K14/705 ; A61K38/17 ; A61K48/00
摘要：
The invention discloses immunogenic CEA agonist polypeptides/proteins comprising a modified epitope containing the amino acid sequence YLSGADLNL, nucleic acids coding therefor, vectors and/or cells comprising said nucleic acids, and mixtures and/or compositions thereof. Methods for eliciting or inducing CEA-specific immune responses utilizing the aforementioned agents are also disclosed.
公开/授权文献
- EP1561817A2 Modified CEA and uses thereof 公开/授权日：2005-08-10
信息查询
IPC分类:
